US5165441032 - Common Stock
LANTHEUS HOLDINGS INC
NASDAQ:LNTH (7/25/2024, 7:00:00 PM)
After market: 112.95 0 (0%)112.95
-0.71 (-0.62%)
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2015-06-25. The firm classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
LANTHEUS HOLDINGS INC
331 Treble Cove Rd
North Billerica MASSACHUSETTS 01862
P: 19786718001
CEO: Mary Anne Heino
Employees: 834
Website: https://www.lantheus.com/
Investors should take note of NASDAQ:LNTH, a growth stock that remains attractively priced.
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference...
Acquisition Expands Pipeline and Strengthens Alzheimer’s Diagnostic Capabilities
Acquisition Expands Pipeline and Strengthens Alzheimer’s Diagnostic Capabilities...
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts.
Here you can normally see the latest stock twits on LNTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: